Loading clinical trials...
Loading clinical trials...
The primary objective of the study was to evaluate the immunogenicity of natalizumab (Tysabri®) produced by a modified manufacturing process (natalizumab high titer; BG00002-E) administered intravenou...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Biogen
Collaborators
NCT06433752 · Relapsing Multiple Sclerosis, Multiple Sclerosis
NCT06846281 · Relapsing Multiple Sclerosis
NCT05644522 · Cerebrovascular Accident, Post-polio Syndrome, and more
NCT07497399 · Multiple Sclerosis
NCT06847724 · Relapsing Multiple Sclerosis
Research Site
Washington D.C., District of Columbia
Research Site
Maitland, Florida
Research Site
Miami, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions